# US 2022/0009978 A1 · Composition for preventing or treating autoimmune disease based on lrr domain of nlrx1 protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0009978 A1
- Document ID: US20220009978A1
- Status: Published application
- Kind: A1
- Application number: 17/205,538
- Filed: 2021-03-18
- Published: 2022-01-13
- Earliest claimed: 2020-07-09
- Assignees: Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University)
- Applicants: Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University)
- Inventors: Je-Min CHOI; Ja-Hyun KOO
- Web page: https://patentgrep.com/patent/US20220009978A1

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/001: {by chemical synthesis}
- C07K 14/4703: {Inhibitors; Suppressors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to a fusion protein including a cell-penetrating peptide and an LRR domain derived from the NLRX1 protein. Since the fusion protein can effectively inhibit and alleviate the disease severity of autoimmune diseases and directly regulates T cell functions, it can be usefully used to treat or prevent autoimmune diseases.

## Claims

### Claim 1

A fusion protein comprising, at one end of (a) a cell-penetrating peptide represented by SEQ ID NO 1, (b) a peptide comprising a LRR domain derived from the NLRX1 protein represented by SEQ ID NO 2.

### Claim 2 (depends on 1)

The fusion protein according to claim 1, wherein the LRR domain is composed of an amino acid sequence represented by SEQ ID NO 3.

### Claim 3 (depends on 1)

The fusion protein according to claim 1, wherein the fusion protein is composed of an amino acid sequence represented by SEQ ID NO 4.

### Claim 4 (depends on 1)

A gene encoding the fusion protein according to claim 1.

### Claim 5 (depends on 4)

A recombinant vector comprising the gene according to claim 4.

### Claim 6 (depends on 5)

A transformant transformed with the recombinant vector according to claim 5.

### Claim 7 (depends on 1, 6)

A pharmaceutical composition comprising the fusion protein according to claim 1 or a recombinant protein isolated from the transformant according to claim 6 as an active ingredient.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, which is for preventing or treating an autoimmune disease.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the autoimmune disease is any one selected from a group consisting of rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, lupus, diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, Sjogren's syndrome, Addison's disease, ocular hepatocellular seizure-epileptic syndrome, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, chronic digestive dysfunction, Goodpasture syndrome, idiopathic thrombocytopenic purpura, optic neuritis, scleroderma, primary dysplasia cirrhosis, Takayasu arteritis, temporal arteritis, autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis, systemic alopecia, Behcet's disease, chronic fatigue, autonomic nystagmus, endometriosis, interstitial cystitis, neuromuscular dystrophy, scleroderma, vulvar pain, multiple sclerosis, neuromyelitis optica, myasthenia gravis, Guillain-Barre syndrome, autoimmune uveitis, acute disseminated encephalomyelitis, autoimmune encephalomyelitis, acute transverse myelitis, autoimmune encephalopathy and chronic inflammatory demyelinating polyneuropathy.

### Claim 10 (depends on 7)

A method for treating a neurological autoimmune disease, comprising administering the pharmaceutical composition according to claim 7 to a patient with an autoimmune disease.
